Ustekinumab for Lupus

Happy New Year!

Our first #RheumJC of 2019 will be Thursday, January 31st at 10pm Eastern Time / 9pm Central Time (click here to find this in your local time zone).

We’ll be discussing the Lancet article: Efficacy and safety of ustekinumab, an IL–12 and IL–23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at